Ministry Facilitates Plasma Downstreaming to Strengthen National Autonomy

RRI.CO.ID, Jakarta - Minister of Health Budi Gunadi Sadikin announced that his ministry will fully facilitate the commercialization of Indonesia's first plasma fractionation factory through strategic partnerships. This initiative is designed to ensure that the domestic downstreaming process runs optimally to secure long-term public health benefits.

Minister Sadikin said that the government will continuously oversee regulations from upstream to downstream sectors. In the short term, the regulatory focus will center on reinforcing the supply side across national plasma centers to guarantee a sustainable and continuous availability of raw materials.

"We will definitely fully support this collaboration and seek the best way to structure it effectively. The government can move forward through integration with institutions like Danantara or synergy with state-owned pharmaceutical holding companies like Bio Farma," Minister Budi Gunadi Sadikin said in Jakarta on Thursday, June 4, 2026, as quoted by Antara.

The Ministry of Health is actively driving this strategic partnership by integrating the government's institutional ecosystem. The minister emphasized that this cooperation must deliver tangible field impacts rather than remaining a mere symbolic agreement on paper.

Looking forward, the government plans to draft a comprehensive, long-term roadmap for Indonesia's healthcare service industry spanning the next 5, 15, and 30 years, encompassing the pharmaceutical, hospital services, and medical equipment sectors.

National health resilience is expected to strengthen substantially if the construction of domestic plasma factories can be accelerated to produce local medicinal raw materials, vaccines, and other innovative therapies.

The government's appreciation for regulatory efficiency and rapid field execution is reflected in the project's massive timeline. Following pivotal regulatory adjustments enacted in 2023, the development has progressed rapidly and is officially targeted to be fully operational by 2027.

During the same event, the President Director of SK Plasma Core Indonesia, Hyunho Roh, expressed his company's readiness to advance into the next phase of development. This expansion will include establishing plasma banks across Indonesia alongside conducting advanced pharmaceutical research.

"We are very grateful for the continuous attention and support from the Ministry of Health. When we first came to the Ministry of Health to ask for a business permit, we promised to build this plasma fractionation factory within two years, and today the factory has been completed. Currently we are waiting for the commercialization process," Hyunho Roh revealed.

The biopharmaceutical company is prepared to embark on this new collaborative journey with Indonesia. The scope of the partnership extends beyond collecting plasma through local blood banks, it also aims to cultivate an entirely new local industrial ecosystem spanning advanced pharmaceuticals, the manufacturing of domestic Active Pharmaceutical Ingredients (APIs), and dedicated vaccine development.

The corporate management reconfirmed that if the Ministry of Health grants them further opportunities, they will deploy their ultimate capabilities to fulfill their long-term commitments to the nation. ***